Business Wire

First Eagle Expands Offering of US Small Cap Strategy to Non-US Investors

21.9.2022 16:00:00 EEST | Business Wire | Press release

Share

First Eagle Investments (“First Eagle”) today announced it has expanded its portfolio offerings to non-US investors through the launch of its US Small Cap strategy within First Eagle’s Irish UCITS platform. The sub-fund, which was seeded by First Eagle in February 2022, pursues an opportunistic small cap value strategy. It invests in companies that the portfolio management team believes are attractively valued and have the potential to benefit from a catalyst—such as new management, a more favorable business cycle, product innovation and/or margin improvement—that may drive a recovery in earnings growth.

The strategy is managed by First Eagle’s Small Cap team, which was formed in April 2021 with the hiring of Portfolio Manager Bill Hench, Associate Portfolio Managers Suzanne Franks and Rob Kosowsky, and Senior Research Analyst Adam Mielnik. All four were previously employed by Royce Investment Partners, where they managed the portfolios of a US mutual fund, a UCITS fund and a collective investment trust, with Hench listed as one of the portfolio managers since 2004. Subsequently, the Small Cap team added Trader/Analyst Mark Salamone and Analyst Connor Sheehy in October 2021 and July 2022, respectively.

“We believe skilled active managers can exploit the ample inefficiencies in the US small cap market to deliver differentiated investment solutions,” said Matthieu Louanges, Global Head of Institutional and International Wealth Management at First Eagle. “Bill and his team have been focused on the US small cap market for many years, and our London and Munich-based account management teams are pleased to offer existing and prospective clients access to this time-tested, value-oriented strategy through a UCITS structure.”

First Eagle’s US Small Cap strategy takes an opportunistic but disciplined approach to bottom-up portfolio construction, employing in-house fundamental research in an effort to identify companies that appear temporarily mispriced by the market due to inefficiently valued assets, turnaround potential, accelerating-but-overlooked earnings growth, or unacknowledged market leadership. True small cap specialists, the team typically holds 180 to 300 stocks—including microcap stocks with market capitalizations below $1 billion—in pursuit of broad diversification at the security level.

“Small cap stocks represent a particularly volatile and inefficiently priced segment of the US equity market,” said Hench. “However, these dynamics historically also have created opportunities for disciplined active managers to generate attractive long-term returns for investors through diversified portfolios of undervalued small cap names. We are excited to offer our expertise in this space to investors outside the US.”

The US Small Cap strategy is offered through a sub-fund of First Eagle’s Irish UCITS vehicle, with three types of share classes (retail, advisory and institutional) denominated in three currencies (US dollars, euros and British pounds). The UCITS fund currently is available for public offer and sale in Austria, Belgium, France, Germany, Ireland, Luxembourg, Netherlands, Portugal and Spain, and is available for eligible investors in Switzerland and the United Kingdom. First Eagle plans to register the UCITS fund for distribution in additional countries in the near future. This latest sub-fund joins First Eagle’s growing UCITS platform, which was established in May 2021 with the launch of a sub-fund offering its International Value (global excluding the US) strategy.

About First Eagle Investments

First Eagle Investments is an independent, privately owned investment management firm headquartered in New York with approximately $101.6 billion in assets under management as of June 30, 2022. (On a pro forma basis to include the recent acquisition of Napier Park Global Capital, First Eagle’s total assets under management are approximately $121.1 billion as of that same date.) Dedicated to providing prudent stewardship of client assets, the firm focuses on active, fundamental and benchmark-agnostic investing, with a strong emphasis on downside mitigation. With a heritage dating back to 1864, First Eagle has helped its clients avoid permanent impairment of capital and earn attractive returns through widely varied economic cycles—a tradition that is central to its mission today. The firm’s investment capabilities include equity, fixed income, alternative credit and multi-asset strategies. For more information on First Eagle, please visit www.firsteagle.com.

The total pro forma assets under management (AUM) represents the combined AUM of First Eagle Investments and Napier Park Global Capital as of June 30, 2022. It includes $1.5 billion of committed and other non-fee-paying capital from First Eagle Alternative Credit and $0.9 billion of committed and other non-fee-paying capital from Napier Park, inclusive of assets managed by Regatta Loan Management LLC. Pro forma results are for illustrative purposes only and are not actual performance results. The pro forma results reflect a business combination that had not yet taken place and may differ materially from actual performance results.

IMPORTANT INFORMATION FOR INVESTORS

This is a marketing communication. The material is for informational purposes only and should not be regarded as a recommendation or an offer to buy or sell any product or service to which this information may relate. Certain products and services may not be available to all entities or persons. This release does not constitute or contain an offer, solicitation, recommendation or investment advice with respect to the purchase of any sub-fund described herein or any security.

The investment vehicle referenced in this material has been established as an Irish collective asset-management vehicle with variable capital constituted as an umbrella fund with segregated liability between its sub-funds under the laws of Ireland (registered number 445369) (the “ICAV”). Prospective investors should carefully consider a sub-fund’s objectives, risks, charges, tax considerations and expenses and other relevant information before investing. For this and more information on the ICAV, please refer to the ICAV’s prospectus, the supplement for the sub-funds and the applicable KIIDs and read them carefully before you invest and before making any final investment decisions. This is not a contractually binding document; do not base any final investment decision on this communication alone.

An investment in a sub-fund involves risk; principal loss is possible. There is no guarantee a sub-fund’s investment objectives will be achieved. In respect of the US Small Cap strategy, investments in small and micro-size companies historically have been more volatile in price than larger company securities, especially over the short term. Positions in small and micro-size companies also may be more difficult or expensive to trade. Among the reasons for the greater price volatility are the less certain growth prospects of small and micro-size companies, the lower degree of liquidity in the markets for such securities, and the greater sensitivity of small and micro-size companies to changing economic conditions. Value investments present the risk of never reaching what may be believed to be their full market values or may decline in value.

More information on these risk considerations, as well as information on other risks to which the sub-fund is subject, such as liquidity, market, and investment strategy risks, are included in the ICAV’s prospectus.

The ICAV’s prospectus is available on the First Eagle website and www.fundinfo.com. The KIIDs can also be accessed on the First Eagle website and are available in one of the official languages of each of the EU Member States into which the sub-funds have been notified for marketing under the UCITS Directive 2009/65/EC.

Prospective investors should also consult their professional advisers as to the suitability of any investment in light of their particular circumstances and applicable citizenship, residence or domicile. The ICAV has been authorized in Ireland as a UCITS pursuant to the European Communities (Undertakings for Collective Investments in Transferable Securities) Regulation 2011, as amended.

Shares of the ICAV are only available for certain non-US persons in select transactions outside the United States, or, in limited circumstances, otherwise in transactions that are exempt from the registration requirements of the United States Securities Act of 1933, as amended, and such other US laws as may be applicable.

The ICAV currently is available for public offer and sale in Austria, Belgium, France, Germany, Ireland, Luxembourg, Netherlands, Portugal and Spain, and is available for eligible investors in Switzerland and the United Kingdom, in each case in accordance with applicable law.

The views expressed herein represent the opinions of First Eagle and are not intended as a forecast or guarantee of future results for any product or service.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Mount and Nadler
Hedda Nadler
hedda@mountandnadler.com
212.759.4440

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release

The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release

VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati

WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 19:00:00 EET | Press release

WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever launched. Every account represents a real person with a verified heartbeat. They have real goals, challenges, and achievements. T

Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 18:00:00 EET | Press release

The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and quantum chemistry to embed safety into chemical design from the outset. Adaptive catalytic systems: Led by the Max Planck Insti

Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 17:00:00 EET | Press release

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical applications. As India continues to play a critical role in supplying medicines to patients around the world, pharmaceutical manufacturers face increasing demands for quality, regulatory compliance,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye